Publications by authors named "M Wermke"
Introduction: Small cell transformation (SCT) is a typical mechanism of adaptive resistance to third generation epidermal growth factor receptor inhibitors (EGFRi) which have become the standard of care for EGFR-driven non-small cell lung cancer (EGFR+ NSCLC). Little is known about the optimal management of SCT patients. This study aimed to compare outcomes under platinum/etoposide chemotherapy alone (chemo) or in combination with EGFR inhibitors (EGFRi+chemo) or immune checkpoint inhibitors (ICI+chemo).
View Article and Find Full Text PDFArticle Synopsis
- The study focused on pairing naporafenib, a pan-RAF inhibitor, with either rineterkib or trametinib to treat patients with non-small cell lung cancer (NSCLC) and certain genetic mutations.
- Conducted on 216 patients, the research aimed to find safe and effective dosage levels, identifying recommended doses while monitoring for side effects and antitumor activity.
- Results showed dose-limiting toxicities in 16% of patients, with some achieving partial responses; the study established specific dosages that were well-tolerated along with noticeable reductions in certain mRNA levels.
Article Synopsis
- * A study of 218 OMD NSCLC patients showed that those with fewer metastases and female patients had significantly longer overall survival rates, with a median OS of 27.8 months and a 5-year survival rate of 29%.
- * Patients who underwent comprehensive local ablation combined with systemic therapy experienced improved recurrence-free survival, highlighting that adding immunotherapy could enhance outcomes, indicating a potential for a curative approach.
Non-small cell lung cancer (NSCLC) is characterized by high recurrence rates in the early stages. In a German cohort, recurrence-free survival after 5 years was 62% (stage IA1), 40.7% (stage IIA) and 28% (stage IIIA).
View Article and Find Full Text PDFBackground: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET amplification as a mechanism of resistance to first-line osimertinib have few treatment options. Here, we report the primary analysis of the phase 2 INSIGHT 2 study evaluating tepotinib, a highly selective MET inhibitor, combined with osimertinib in this population.
Methods: This open-label, phase 2 study was conducted at 179 academic centres and community clinics in 17 countries.